65 Equity Partners

Apex

Apex Healthcare (“Apex”) is a leading Southeast Asian pharmaceutical company with deep capabilities across branded generics, consumer health products, and distribution services. Headquartered in Singapore, with an expanding presence across Malaysia and Singapore, Apex develops, manufactures, markets and distributes a broad portfolio of pharmaceutical and consumer healthcare products that serve both prescription and over the counter segments. The company is recognised for its high-quality branded generics Xepa, and longstanding reputation in community healthcare, supported by an integrated supply chain and extensive distribution network.

Apex operates across the full value chain — from R&D and manufacturing to sales, marketing, warehousing and distribution — enabling it to deliver reliable, affordable, and quality assured medicine to clinics, pharmacies, and hospitals throughout the region.

Who we partnered with

65 Equity Partners is working closely with our shareholder partners and Apex’s seasoned management team to support the company’s next phase of growth. We aim to leverage our global and Singapore network to help Apex strengthen its presence in Singapore as a strategic hub for regional expansion and as an anchor for their value-creation strategy.

What attracted us to the business

Apex’s mission aligns strongly with our thematic focus on essential healthcare, quality generics, and broad-based access to medical products across Asia. The company’s robust manufacturing and distribution capabilities provide a scalable platform for product expansion and regional growth into the wider ASEAN region. Combined with a high quality, execution focused management team, and a clear pathway to unlock further value through capacity enhancements, portfolio deepening and commercial strengthening, Apex represents an opportunity to support an essential healthcare champion on its growth journey.

Our value creation strategy

65 Equity Partners will work closely with our partners to drive both organic expansion and strategic M&A activities, with the goal of building a leading regional integrated pharmaceutical and consumer health platform anchored in Singapore. Our value creation strategy focuses on accelerating R&D pipelines and strengthening external partnerships to bring new drugs to market faster; expanding consumer health presence by leveraging Apex’s strong distribution network; strengthening Apex’s regional presence in Southeast Asia; and driving operational excellence across business segments.

Website: https://apexhealthcare.com.my/#home

Allied OMS

Founded by surgeons, for surgeons, Allied OMS is a premier, physician-led management services organization (MSO) that partners with leading oral and maxillofacial surgery (OMS) practices across the United States. Since its inception in 2020, Allied has built a differentiated, physician-centric platform that combines clinical excellence with operational and strategic expertise. Today, Allied supports a growing network of more than 50 high-quality practices nationwide, helping surgeons enhance patient care while scaling their businesses.

Who we partnered with

65 Equity Partners is proud to partner with Allied’s founding team, CEO Dan Hosler, and over 50 physician-owners who share a commitment to exceptional outcomes and a long-term vision for the specialty. This transaction brings in co-investors Everberg, Comvest, and Aquarian, who are also supporting the debt financing.

What attracted us to the business

We were drawn to Allied’s unique model that puts physicians at the center—attracting the best surgeons in the country and aligning incentives to deliver superior care. The business is well-positioned to capitalize on strong secular trends: increasing demand for oral healthcare, growing patient volumes, and significant white space for consolidation in a highly fragmented sector. Allied’s culture of clinical leadership and focus on patient-first care stood out as a compelling foundation for sustainable growth.

Our value creation strategy

Our investment will support Allied in expanding its service offering, scaling core operational capabilities, and executing a robust acquisition strategy—all while preserving its physician-led ethos. We see opportunities to accelerate organic growth, expand access to high-quality oral healthcare across more communities, and create enduring value for patients, physicians, and stakeholders alike.

Website: https://alliedoms.com/

Kee Safety

Founded in 1934, Kee Safety is a global leader in safety equipment.
The company specializes in the design, installation, and certification of safety systems, offering innovative solutions for fall protection, safe access and ground safety to separate people from hazards.

Since inception, the Company has significantly expanded its product range and global footprint, with sales into 60 countries across the US, Europe, Asia, and the Middle East.

Kee Safety remains committed to innovation, leveraging its world-class testing facilities and expertise in international safety markets to drive new product developments.

Who we partnered with

65 Equity Partners partnered with Chairman Chris Milburn and the company’s long-tenured management team, alongside co-investors Inflexion and ICG.

What attracted us to the business

With strong presence in all safety verticals, Kee Safety offers the most comprehensive range of high-quality products, delivered through a vertically integrated installer model.

In a highly fragmented market, Kee Safety has demonstrated an impressive track record of organic and acquisitive growth with over 54 businesses acquired to date and a healthy pipeline for future M&A.

Kee Safety is well positioned to capitalize on long-term structural growth drivers around increasing compliance and regulatory requirements and awareness for health & safety.

Our value creation strategy

We will work closely with the Kee Safety team to support international expansion and M&A, leveraging our global footprint.

Website: https://www.keesafety.com/

HAS / Cerbios

HAS Healthcare Advanced Synthesis SA (“HAS”), a leading international developer and producer of active pharmaceutical ingredients (APIs), high-potency APIs, and anticancer compounds acquired Cerbios-Pharma SA (“Cerbios”), a globally recognised manufacturer of chemical and biological APIs, including in the rapidly expanding area of antibody drug conjugates.

This strategic transaction marks a significant milestone for the two companies and sets the stage for the creation of a leading global solutions provider in the Contract Development and Manufacturing Organization industry.

Who we partnered with

HAS, owned by the Braglia family, acquired Cerbios which was itself owned by several families. 65 Equity Partners backed the merger, partnering with these family businesses and entrepreneurs in this acquisition.

What attracted us to the business

The alliance of the two Swiss-based companies, both with a global market presence, will drive innovation, accelerate extensive high-quality production capabilities, and deliver the cutting-edge chemical and biological expertise, technical excellence, and a wider range of services to address the dynamic needs of the global pharmaceutical industry.

Our value creation strategy

With the strategic backing of 65 Equity Partners to drive long-term company growth and innovation, the new group is uniquely positioned for growth in an industry underpinned by strong structural tailwinds.

Website: hashealthcare.com